Fulltext

Differences in High Dose Antipsychotic Prescriptions in Patients with Schizophrenia in Asian Countries/Areas: Findings from the REAP-AP Study

Park YC 1 , Yang SY 2 , Chong MY 3 , Kanba S 4 , Sartorius N 5 , Shinfuku N 6 Show all authors , Tan CH 7 , Park SC 8

Affiliations 

  • 1 Department of Neuropsychiatry, Hanyang University Guri Hospital, Guri, Republic of Korea
  • 2 Deparment of Pharmacy, Songde Branch, Tapei City Hospital, Tapei, Taiwan
  • 3 Department of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University School of Medicine, Kaohsiung, Taiwan
  • 4 Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • 5 Association for the Improvement of Mental Health Programs, Geneva, Switzerland
  • 6 Department of Social Welfare, School of Human Sciences, Seinan Gakuin University, Fukuoka, Japan
  • 7 Department of Pharmacology, National University Hospital, Singapore
  • 8 Department of Psychiatry, Inje University College of Medicine and Haeundae Paik Hospital, Busan, Republic of Korea
Psychiatry Investig, 2018 Oct;15(10):1007-1008.
PMID: 30373360 DOI: 10.30773/pi.2018.09.06

Abstract

The REAP-AP study recruited 3,746 patients with schizophrenia, in March and April 2016, from 71 centers in 15 Asian countries/territories namely Bangladesh, China, Hong Kong, India, Indonesia, Japan, Korea, Malaysia, Myanmar, Pakistan, Singapore, Sri Lanka, Taiwan, Thailand and Vietnam. Our findings reveal a trend according to which high dose antipsychotic prescription is more prevalent in Eastern Asia (especially, Japan and Korea) than in other regions of Asia. This historical factor may be associated with our finding of an Eastern Asian preponderance of high dose antipsychotic prescription.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications